Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims…

PHILADELPHIA, Aug. 18, 2026 (GLOBE NEWSWIRE) --

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY):

Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY).

What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares prior to March 9, 2026, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/ars-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  

What is Alleged? It is alleged in a recently filed federal securities fraud class action complaint that ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) certain corporate officers knew or recklessly disregarded potential timeline issues with CVS Caremark’s formulary addition and coverage decision related to neffy; (ii) the guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and (iii) the expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.

On June 24, 2026, after the market closed, ARS Pharmaceuticals published a press release announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, the price of ARS Pharmaceuticals stock declined nearly 24%, according to the complaint.

What Can You Do Now? If you purchased ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares prior to March 9, 2026, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/ars-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. #SPRY $SPRY #ARSPharmaceuticals

Bloom Energy Corporation (NYSE: BE):

Grabar Law Office is investigating claims on behalf of shareholders of Bloom Energy Corporation (NYSE: BE).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Bloom Energy Corporation (NYSE: BE) shares prior to February 27, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. Please visit https://grabarlaw.com/the-latest/bloom-energy-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

What is Alleged? According to a recently filed federal securities class action lawsuit, Bloom Energy Corporation (NYSE: BE), through certain of its offciers, made false and/or misleading statements and/or failed to disclose that: (i) Bloom Energy obtained scandium through intermediaries who sourced the metal from China; (ii) as a result, Bloom Energy understated the extent to which it relied on scandium from China; and (iii) as a result of the foregoing, defendants’ positive statements about Bloom Energy’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 8, 2026, Hunterbrook Media published a report titled “Bloom’s Big Lie,” which alleged, among other things, that “Bloom is, in fact, reliant on Chinese scandium, according to global trade data, Chinese corporate filings, satellite imagery, and Hunterbrook’s messages with Bloom’s suppliers in China.” The report allegedly states “Hunterbrook traced four separate China-linked routes into Bloom’s supply chain – scandium oxide shipped directly to its Delaware plant, plus scandium-bearing ceramics and powders flowing through intermediaries in Thailand, Japan, and South Korea.” On this news, the price of Bloom Energy stock fell nearly 6%, according to the complaint.

What Can You Do Now? If you purchased Bloom Energy Corporation (NYSE: BE) shares prior to February 27, 2025, and still hold shares today, please visit https://grabarlaw.com/the-latest/bloom-energy-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. #BE $BE #BloomEnergy

GPGI, INC., F/K/A COMPOSECURE, INC. (NYSE: GPGI; CMPO):

Grabar Law Office is investigating claims on behalf of shareholders of GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO).

What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

What Is Alleged? It is alleged in a recently filed federal securities fraud class action complain that GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) defendants had materially overstated the value of Husky; (ii) Husky was not on track to achieve the revenue and Adjusted EBITDA targets provided in the proxy statement and such targets lacked a reasonable basis in objective fact; (iii) a primary motivation of the Husky Acquisition was to generate millions of dollars in fees for Resolute Holdings and the individual defendants, rather than to create long-term value for CompoSecure shareholders; and (iv) as a result of the above, defendants had materially misrepresented the business, prospects, and expected financial results of GPGI and Husky as a combined business.

What Can You Do Now? If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. Alternatively, if you purchased GPGI, Inc., f/k/a CompoSecure, Inc. securities between November 3, 2025 and May 6, 2026, you can participate in the class action. #GPGI $GPGI #CompoSecure $CMPO

Insulet Corporation (NASDAQ: PODD):

Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).

What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

What Is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth began to emerge on March 12, 2026, when Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” Then, on May 26, 2026, Insulet disclosed the “initat[ion]” of another “voluntary Medical Device Correction” (the “May 2026 MDC”), this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.”

What Can You Do Now? If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Insulet, #PODD $PODD

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com